CA2500498C - Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations - Google Patents
Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations Download PDFInfo
- Publication number
- CA2500498C CA2500498C CA2500498A CA2500498A CA2500498C CA 2500498 C CA2500498 C CA 2500498C CA 2500498 A CA2500498 A CA 2500498A CA 2500498 A CA2500498 A CA 2500498A CA 2500498 C CA2500498 C CA 2500498C
- Authority
- CA
- Canada
- Prior art keywords
- group
- cftr
- hydroxyl
- nitro
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
L'invention concerne des compositions, des préparations pharmaceutiques et des procédés permettant d'inhiber la protéine CFTR, utiles pour l'étude et le traitement des maladies dont la médiation est assurée par la protéine CFTR. Les compositions et les préparations pharmaceutiques peuvent comprendre un ou plusieurs composés thiazolidinone, et par ailleurs un ou plusieurs vecteurs, excipients et/ou adjuvants pharmaceutiquement acceptables. Les procédés consistent, selon certaines variantes, à administrer au patient soufrant d'une maladie ou d'une affection dont la médiation est assurée par la protéine CFTR une quantité efficace de composé thiazolidinone. Sous d'autres variantes, on décrit des procédés inhibant la protéine CFTR qui consistent à mettre en contact des cellules du patient avec une quantité efficace de composé thiazolidinone. L'invention concerne également un modèle animal non humain de maladie dont la médiation est assurée par la protéine CFTR, résultant de l'administration d'un composé thiazolidinone à un animal non humain, en quantité suffisante pour inhiber la protéine CFTR.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/262,573 | 2002-09-30 | ||
US10/262,573 US20040063695A1 (en) | 2002-09-30 | 2002-09-30 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
US48025303P | 2003-06-20 | 2003-06-20 | |
US60/480,253 | 2003-06-20 | ||
PCT/US2003/031005 WO2004028480A2 (fr) | 2002-09-30 | 2003-09-30 | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2500498A1 CA2500498A1 (fr) | 2004-04-08 |
CA2500498C true CA2500498C (fr) | 2012-08-21 |
Family
ID=32044981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2500498A Expired - Fee Related CA2500498C (fr) | 2002-09-30 | 2003-09-30 | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1549321A4 (fr) |
JP (1) | JP4977319B2 (fr) |
KR (1) | KR20050061501A (fr) |
CN (1) | CN100356922C (fr) |
AP (1) | AP2005003292A0 (fr) |
AU (1) | AU2003277162C1 (fr) |
BR (1) | BR0314943A (fr) |
CA (1) | CA2500498C (fr) |
EA (1) | EA009847B1 (fr) |
MX (1) | MXPA05003366A (fr) |
NZ (1) | NZ538809A (fr) |
PL (1) | PL376147A1 (fr) |
WO (1) | WO2004028480A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8796321B2 (en) | 2008-04-21 | 2014-08-05 | Path Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
HUE055205T2 (hu) | 2006-04-07 | 2021-11-29 | Vertex Pharma | ATP-kötõ kazetta transzporterek modulátorainak elõállítása |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
CN101668732A (zh) | 2007-04-02 | 2010-03-10 | 同一世界健康研究院 | Cftr抑制剂化合物及其用途 |
ES2578735T3 (es) * | 2007-08-24 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística |
US8507524B2 (en) | 2007-11-16 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette-transporters |
US8507534B2 (en) | 2007-12-07 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
EP2279029A2 (fr) * | 2008-03-25 | 2011-02-02 | The Regents of the University of California | Inhibiteurs à petite molécule soluble dans l eau du régulateur de conductance transmembranaire de fibrose kystique |
US8227615B2 (en) | 2008-03-31 | 2012-07-24 | Vertex Pharmaceutical Incorporated | Pyridyl derivatives as CFTR modulators |
US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
EP2490696A1 (fr) * | 2009-10-20 | 2012-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement des troubles de l'homéostasie du glucose |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
RU2711481C2 (ru) | 2010-03-25 | 2020-01-17 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА |
AR081069A1 (es) | 2010-04-07 | 2012-06-06 | Vertex Pharma | Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
CA2797118C (fr) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Procede de production de composes de cycloalkylcarboxamido-indole |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
US20120046330A1 (en) | 2010-08-23 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
JP6014816B2 (ja) | 2011-05-10 | 2016-10-26 | 国立大学法人神戸大学 | Ras機能阻害作用を有するチオキソチアゾリジン誘導体 |
EP2776427B1 (fr) | 2011-11-08 | 2017-02-01 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de cassette de liaison à l'atp |
CA3128556A1 (fr) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations d'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoique |
EP2872122A1 (fr) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration |
SG10201703452PA (en) | 2012-11-02 | 2017-06-29 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
FR2999191B1 (fr) | 2012-12-12 | 2016-02-05 | Lesaffre & Cie | Souches probiotiques pour le traitement et/ou la prevention de la diarrhee |
KR102447581B1 (ko) | 2014-04-15 | 2022-09-28 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물 |
PL3203840T3 (pl) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
CN104398509B (zh) * | 2014-11-13 | 2017-01-11 | 四川大学华西第二医院 | CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用 |
CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
EP3394083B9 (fr) | 2015-12-24 | 2022-04-27 | The Regents of the University of California | Dérivés de n-[5-[(3,4-diméthoxyphenyl)méthyl]-1,3,4-thiadiazol-2-yl]-2-méthoxy-benzeneacétamide et composés similaires en tant qu'activateurs cftr pour le traitement de constipation ou cholestasis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9010041B (en) * | 1989-12-21 | 1992-08-26 | Lilly Co Eli | Compounds for treating inflammatory bowel disease |
WO1995013075A1 (fr) * | 1993-11-12 | 1995-05-18 | Cell Therapeutics, Inc. | Procede pour eviter les lesions des tissus provoquees par l'hypoxemie |
UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
KR20010099623A (ko) * | 1998-08-21 | 2001-11-09 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 |
US6484397B1 (en) * | 2000-07-11 | 2002-11-26 | Corning Incorporated | Method of assembling a catalytic converter for use in an internal combustion engine |
US20020052396A1 (en) * | 2001-04-23 | 2002-05-02 | Bailey Thomas R. | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
-
2003
- 2003-09-30 AU AU2003277162A patent/AU2003277162C1/en not_active Ceased
- 2003-09-30 CA CA2500498A patent/CA2500498C/fr not_active Expired - Fee Related
- 2003-09-30 KR KR1020057005551A patent/KR20050061501A/ko active IP Right Grant
- 2003-09-30 BR BR0314943-9A patent/BR0314943A/pt not_active IP Right Cessation
- 2003-09-30 EA EA200500583A patent/EA009847B1/ru not_active IP Right Cessation
- 2003-09-30 EP EP03798805A patent/EP1549321A4/fr not_active Withdrawn
- 2003-09-30 PL PL03376147A patent/PL376147A1/xx not_active Application Discontinuation
- 2003-09-30 CN CNB038233665A patent/CN100356922C/zh not_active Expired - Fee Related
- 2003-09-30 JP JP2004540305A patent/JP4977319B2/ja not_active Expired - Fee Related
- 2003-09-30 MX MXPA05003366A patent/MXPA05003366A/es active IP Right Grant
- 2003-09-30 AP AP2005003292A patent/AP2005003292A0/xx unknown
- 2003-09-30 NZ NZ538809A patent/NZ538809A/en not_active IP Right Cessation
- 2003-09-30 WO PCT/US2003/031005 patent/WO2004028480A2/fr active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8796321B2 (en) | 2008-04-21 | 2014-08-05 | Path Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
Also Published As
Publication number | Publication date |
---|---|
CN100356922C (zh) | 2007-12-26 |
AP2005003292A0 (en) | 2005-06-30 |
WO2004028480A3 (fr) | 2004-07-01 |
EP1549321A4 (fr) | 2007-05-23 |
EP1549321A2 (fr) | 2005-07-06 |
JP2006503853A (ja) | 2006-02-02 |
MXPA05003366A (es) | 2005-10-05 |
BR0314943A (pt) | 2005-08-02 |
PL376147A1 (en) | 2005-12-27 |
EA009847B1 (ru) | 2008-04-28 |
AU2003277162C1 (en) | 2009-12-24 |
AU2003277162B2 (en) | 2009-07-16 |
CN1684686A (zh) | 2005-10-19 |
JP4977319B2 (ja) | 2012-07-18 |
KR20050061501A (ko) | 2005-06-22 |
WO2004028480A2 (fr) | 2004-04-08 |
NZ538809A (en) | 2008-06-30 |
CA2500498A1 (fr) | 2004-04-08 |
EA200500583A1 (ru) | 2005-12-29 |
AU2003277162A1 (en) | 2004-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2500498C (fr) | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations | |
US7638543B2 (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
ZA200502517B (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | |
US7888332B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
EP0760657B9 (fr) | Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation | |
KR20070114820A (ko) | 돌연변이-cftr 처리를 보정하는데 활성을 가지는화합물 및 이것의 사용 | |
US20080027052A1 (en) | Methods for treating cystic kidney disease | |
WO2000035867A1 (fr) | Nouveaux ligands d'un recepteur nucleaire | |
DE69736130T2 (de) | Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen | |
KR20020093983A (ko) | 포스페이트 수송 억제제 | |
CA2761597C (fr) | Agent antichoc comportant un derive de diaminotrifluoromethylpyridine | |
DE69931814T2 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
JPS6056920A (ja) | 脂質レベルの低減方法 | |
KR20080111021A (ko) | 철 대사 장애의 치료를 위한 스트로빌루린의 용도 | |
JP2008037753A (ja) | 掻痒の治療及び/又は予防剤 | |
JPH01305029A (ja) | テトラゾール誘導体の使用 | |
JPH0648942A (ja) | 抗高脂血症剤及び抗動脈硬化症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140930 |